4-(4-methylpiperazin-1-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline | 1217300-78-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-methylpiperazin-1-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline
• CAS: 1217300-78-1
• 化学式: C₁₅H₁₅F₃N₆
• 分子量: 336.32
• InChiKey: QZRYGWNQHCGXSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2,3-二氯-6-(三氟甲基)喹噁啉 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 1.5h， 生成 4-(4-methylpiperazin-1-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline
  参考文献：
  名称：

  [EN] HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
  [FR] INHIBITEURS HÉTÉROCYCLIQUES DE RÉCEPTEURS DE L'HISTAMINE DESTINÉS AU TRAITEMENT DE MALADIE

  摘要：

  公开号：

  WO2011112731A3

文献信息

• HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
  申请人：Borchardt Allen J.

  公开号：US20100120741A1

  公开（公告）日：2010-05-13

  The present invention relates to compounds and methods which may be useful as inhibitors of H 1 R and/or H 4 R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

  本发明涉及化合物和方法，这些化合物和方法可能用作H1R和/或H4R的抑制剂，用于治疗或预防炎症性、自身免疫性、过敏性和眼部疾病。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALLERGY
  申请人：Beauregard Clay

  公开号：US20120015953A1

  公开（公告）日：2012-01-19

  The present invention relates to compositions comprising an antagonist of the histamine H1 receptor and a compatible antagonist of the histamine H4 receptor. The antagonist compounds are selected to prevent the H4 receptor antagonist from interfering with the H1 receptor antagonist's suppression of acute phase allergic responses in a patient. The present invention also relates to compositions comprising a mast cell stabilizer and a compatible antagonist of the histamine H4 receptor.
• [EN] HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS HÉTÉROCYLIQUES DES RÉCEPTEURS DE L'HISTAMINE DESTINÉS AU TRAITEMENT D'UNE MALADIE
  申请人：KALYPSYS INC

  公开号：WO2010030785A2

  公开（公告）日：2010-03-18

  The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALLERGY<br/>[FR] MÉTHODES ET COMPOSITIONS UTILISÉES POUR LE TRAITEMENT DE L'ALLERGIE
  申请人：ALCON RES LTD

  公开号：WO2012012264A1

  公开（公告）日：2012-01-26

  The present invention relates to compositions comprising an antagonist of the histamine H1 receptor and a compatible antagonist of the histamine H4 receptor. The antagonist compounds are selected to prevent the H4 receptor antagonist from interfering with the H1 receptor antagonist's suppression of acute phase allergic responses in a patient. The present invention also relates to compositions comprising a mast cell stabilizer and a compatible antagonist of the histamine H4 receptor.
• [EN] HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE RÉCEPTEURS DE L'HISTAMINE DESTINÉS AU TRAITEMENT DE MALADIE
  申请人：KALYPSYS INC

  公开号：WO2011112731A3

  公开（公告）日：2012-01-12